Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.
about
Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremiaIn vitro activity of daptomycin against Enterococcus faecalis under various conditions of growth-phases, inoculum and pHAntimicrobial resistance status of Enterococcus from Australian cattle populations at slaughter.Genetic basis for daptomycin resistance in enterococci.Identification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility.Decolonization of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium: case series and review of literature.Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review.Comparative analysis of the complete genome of an epidemic hospital sequence type 203 clone of vancomycin-resistant Enterococcus faeciumEnterococcal endocarditis: can we win the war?Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.De novo daptomycin-nonsusceptible enterococcal infections.Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs PatientsTrends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010Differential Effects of Penicillin Binding Protein Deletion on the Susceptibility of Enterococcus faecium to Cationic Peptide AntibioticsDaptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible enterococcus.Intrinsic and acquired resistance mechanisms in enterococcus.Genetic modifications to temperate Enterococcus faecalis phage Ef11 that abolish the establishment of lysogeny and sensitivity to repressor, and increase host range and productivity of lytic infection.Multicenter study of high-dose daptomycin for treatment of enterococcal infectionsA current perspective on daptomycin for the clinical microbiologist.Daptomycin-Vancomycin-Resistant Enterococcus faecium Native Valve Endocarditis: Successfully Treated With Off-Label Quinupristin-Dalfopristin.Frequency of susceptibility testing for patients with persistent methicillin-resistant Staphylococcus aureus bacteremia.Current and prospective treatments for multidrug-resistant gram-positive infections.The zoonotic potential of daptomycin non-susceptible enterococci.Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.Vancomycin-resistant enterococcal bacteremia pharmacotherapy.Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium.Therapeutic options for vancomycin-resistant enterococcal bacteremia.Enterococcal endocarditis revisited.Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.Daptomycin nonsusceptible vancomycin resistant Enterococcus bloodstream infections in patients with hematological malignancies: risk factors and outcomes.Phenylthiazole Antibacterial Agents Targeting Cell Wall Synthesis Exhibit Potent Activity in Vitro and in Vivo against Vancomycin-Resistant Enterococci.Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditiVancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors.Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.Characterization of daptomycin non-susceptible Enterococcus faecium producing urinary tract infection in a renal transplant recipient.What's New in the Treatment of Enterococcal Endocarditis?Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium.False daptomycin-nonsusceptible MIC results by Microscan panel PC 29 relative to Etest results for Staphylococcus aureus and enterococci.Performance of Vitek 2 for antimicrobial susceptibility testing of Staphylococcus spp. and Enterococcus spp.
P2860
Q28302184-A01CA742-FED6-4876-8527-575FCF0E61BBQ28488311-DFB9268C-BD7B-45A3-9232-A6C6AFD8B74CQ33703920-CA385C77-883F-4E00-8977-8282D3BE737CQ33876255-95372253-5EFB-4F7C-AC18-E21A25C062FCQ34058360-4FA47B71-9EC7-433E-9270-9BEECC161DD0Q34271283-124225DC-1DC0-47D3-8B67-FBFC6F6412D0Q34871254-FC5E36B1-C01B-4E04-8C8D-CEB17F9484EDQ34978334-40C54D62-35B3-4295-9933-D79E86386250Q35610638-7774A707-12F6-4619-AAEA-4940B8FC0D5BQ35689222-11269076-EA9F-461F-9558-AADA3EB0CE0AQ35746209-21740D97-27C3-432A-9D72-7CBD3125F198Q35844661-43929048-13E5-492A-B2B9-91CFA9848353Q35999714-C155A655-6CC1-448C-B382-2AF52F71D291Q36018925-4BD7131A-24F1-47A5-8AD6-58C2379A9B07Q36075839-C846B1CC-4280-4B55-AEAF-513DCAB523BBQ36217683-6D0BF36F-D248-4F2B-B988-5E52A0AB30B1Q36362547-B712AA2E-B529-45BD-A9E9-3FB2D170C2A4Q37007036-1B949B76-3782-42E3-B8EB-B31E7A923C68Q37124177-0EA5F003-5ECA-4F4F-891B-3D1D99A22D20Q37263289-3C9FEB55-3EE2-4432-9117-68610989D82AQ37265349-AA6D0815-B1C4-4339-8065-9617C5205E52Q37546815-BDFABF0E-9AB3-4829-A65E-E85B43878B98Q38123255-39FBEAB5-F8BE-406E-923E-F4BBE394B2C0Q38166035-1668FBA7-5410-4317-A67C-BA2A684E6151Q38255366-8888BD96-8960-43F8-982A-1BBB11A0A177Q38263421-D4AE52F2-BA7B-4ABF-BED8-D1BDD04048DFQ38325502-7419235A-8ACF-42F3-BA66-DB5533BDB8B4Q38347869-A020CFD2-467C-4945-84EA-7A4FC5A9D973Q38539279-BCF00769-9427-4D64-B5DD-A32C791BDDE9Q38620812-ED5FFC69-4352-4703-AB95-1554420EDA0EQ40254524-CB9F3540-B082-496A-A784-E79BEF61688DQ40313144-53E8360C-727B-422B-86E5-88A2E4EED330Q40330828-AEA74E5B-0F04-452E-9006-129A7110B078Q40676263-7F051FEF-BBA8-4EC2-910C-21C3BBC9E21FQ40947815-E282278F-607F-48F7-BA32-6E6083962DB9Q41096202-C1F0B690-5254-40A0-B60A-3D8D097E4835Q41368979-166E7A31-7624-4204-ACB9-F503E8D38752Q41570641-86910EBE-8ED3-4DC6-B725-7D1E08471040Q41838887-0D09DFCF-5FA6-4137-BAB1-CF92B6AC6F76Q41908540-E0B7669C-DC8C-42D2-9C82-E021BF86C8D4
P2860
Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.
@en
Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.
@nl
type
label
Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.
@en
Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.
@nl
prefLabel
Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.
@en
Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.
@nl
P2093
P2860
P356
P1476
Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.
@en
P2093
Daniel Z Uslan
David A Pegues
Romney Humphries
P2860
P304
P356
10.1093/CID/CIQ113
P407
P577
2011-01-01T00:00:00Z